US equities |
MU $931.24 ▲+1.87% NVDA $217.23 ▼-1.84% SNDK $1,394.83 ▼-0.61% AMD $562.23 ▼-1.50% SPCX $148.62 ▼-2.33% INTC $95.37 ▼-2.80% AAPL $342.00 ▼-0.28% MSFT $539.44 ▲+1.08%
FinancialContent

Zivo Bioscience, Inc. - Common Stock (OP:ZIVO)

6.514 UNCHANGED
Delayed Quote Updated: 3:53 PM EDT, Oct 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zivo Bioscience, Inc. - Common Stock

News headline image
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th
Company Executives Share Strategic Vision and Engage with Investors Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
ZIVO Stock Earnings: Zivo Bioscience Reported Results for Q2 2024 ↗
Zivo Bioscience just reported results for the second quarter of 2024. 
Via InvestorPlace
News headline image
ZIVO Bioscience Secures Commercial-Scale Manufacturing Agreement with Cyanotech Corporation for Zivolife™ Algal Biomass
From Zivo Bioscience, Inc.
Via Business Wire
News headline image
ZIVO Bioscience Provides Special Letter to Shareholders
From ZIVO Bioscience, Inc.
Via Business Wire
News headline image
ZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic Businesses
From ZIVO Bioscience, Inc.
Via Business Wire
News headline image
ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO’s Immune-Enhancing Compounds in Poultry
From ZIVO Bioscience, Inc.
Via Business Wire
News headline image
University of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry
From ZIVO Bioscience, Inc.
Via Business Wire
News headline image
ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry
From ZIVO Bioscience, Inc.
Via Business Wire
News headline image
ZIVO Bioscience to Present at The Microcap Conference 2025
From Zivo Bioscience, Inc.
Via Business Wire
News headline image
ZIVO Bioscience Reports Progress with Coccidiosis Treatment Licensing Opportunities
From Zivo Bioscience, Inc.
Via Business Wire
News headline image
ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza
From Zivo Bioscience, Inc.
Via Business Wire
News headline image
ZIVO Reports Favorable Results from 42-Day Confirmatory Study of its Coccidiosis Treatment in Broiler Chickens
From ZIVO Bioscience, Inc.
Via Business Wire
News headline image
Major Global Animal Health Company Launches 42-Day Confirmatory Study with ZIVO Bioscience’s Coccidiosis Treatment in Broiler Chickens
From ZIVO Bioscience, Inc.
Via Business Wire